DJI46,429.49+0.66%
GDAXI22,575.48-1.66%
GSPC6,591.90+0.54%
HSI24,856.43-1.89%
IXIC21,929.83+0.77%
N22553,603.65-0.27%
AAPL252.62+0.39%
AMZN211.71+2.16%
CL93.63+3.66%
EURUSD1.1562-0.03%
GBPUSD1.3350-0.13%
GC4,420.10-2.90%
GOOG289.59+0.13%
JPM295.42+1.03%
META594.89+0.33%
MSFT371.04-0.46%
NVDA178.68+1.99%
TSLA385.95+0.76%
DJI46,429.49+0.66%
GDAXI22,575.48-1.66%
GSPC6,591.90+0.54%
HSI24,856.43-1.89%
IXIC21,929.83+0.77%
N22553,603.65-0.27%
AAPL252.62+0.39%
AMZN211.71+2.16%
CL93.63+3.66%
EURUSD1.1562-0.03%
GBPUSD1.3350-0.13%
GC4,420.10-2.90%
GOOG289.59+0.13%
JPM295.42+1.03%
META594.89+0.33%
MSFT371.04-0.46%
NVDA178.68+1.99%
TSLA385.95+0.76%
DJI46,429.49+0.66%
GDAXI22,575.48-1.66%
GSPC6,591.90+0.54%
HSI24,856.43-1.89%
IXIC21,929.83+0.77%
N22553,603.65-0.27%
AAPL252.62+0.39%
AMZN211.71+2.16%
CL93.63+3.66%
EURUSD1.1562-0.03%
GBPUSD1.3350-0.13%
GC4,420.10-2.90%
GOOG289.59+0.13%
JPM295.42+1.03%
META594.89+0.33%
MSFT371.04-0.46%
NVDA178.68+1.99%
TSLA385.95+0.76%
CYBERETIKAGLOBAL FINANCIAL INTELLIGENCE
LIVE
USA Seeking Alpha EN

Armata Pharmaceuticals GAAP EPS of -$3.42, revenue of $1.1M

Mar 26, 2026 &03112626202631; 08:11 UTC seekingalpha.com Trending 3/5
Read original on seekingalpha.com ↗
↘
Negative for markets
Sentiment score: -78/100
High impact Immediate effect (hours)
WHAT THIS MEANS
Armata Pharmaceuticals reported a massive GAAP loss of -$3.42 per share with only $1.1M in revenue, indicating severe cash burn and minimal commercial traction. This is a fresh earnings miss that reveals fundamental business deterioration, likely to trigger sharp selling pressure in a biotech micro-cap with limited runway.
AI CONFIDENCE
72% High
SENTIMENT GAUGE
NEWS POWER SCORE
AFFECTED ASSETS
↓
ARMP
ARMPStock
Expected to decline
Catastrophic earnings miss: -$3.42 EPS with only $1.1M revenue signals severe cash burn, failed commercialization, and existential risk for biotech micro-cap. Fresh news (3 min old) not yet fully absorbed by market. High probability of gap-down open and continued selling as investors reassess survival prospects.
⇅
Biotech SPDR
XBIETF
High volatility expected
Biotech ETF may see modest pressure from ARMP weakness, but diversified holdings limit direct impact. Monitor for broader biotech sentiment shift if other micro-caps report similar distress.
PRICE HISTORY
Loading chart...
⚡ SUGGESTED ACTION
SHORT ARMP on open or use put spreads if liquid. Biotech micro-caps with this loss profile and minimal revenue face existential pressure; expect 8-15% downside as market reprices survival odds. Avoid if illiquid — execution risk may exceed reward. [MOVE:-8.5%]
KEY SIGNALS
Massive GAAP loss (-$3.42 EPS)Minimal revenue ($1.1M) — near-zero commercializationSevere cash burn trajectoryFresh earnings catalyst (3 min old)Micro-cap liquidity riskVIX elevated (+4.82%) — risk-off environment amplifies selling
SECTORS INVOLVED
HealthcareBiotechnology
Analysis generated on Mar 26, 2026 at 08:15 UTC
Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

RELATED INTELLIGENCE

Equitable and Corebridge in talks on all-stock merger to form $22B wealth and retirement giant: report
Seeking Alpha Mar 26, 09:51 Positive
USA uppges skissa på ”nådastöt” mot Iran
Dagens Industri Mar 26, 09:39 Negative
Brittiskt stopp för kinesisk turbintillverkare – dansk rival lyfter
Dagens Industri Mar 26, 09:37 Positive
Carlyle and KKR to build two $2B data centers for U.S. Army, FT reports
Seeking Alpha Mar 26, 09:30 Positive
Brittiskt stopp för kinesisk turbintillverkare – danska rivalen lyfter
Dagens Industri Mar 26, 09:29 Positive